| Clinicopathologic factors |
| Disease stage; tumor size |
Prognostic |
Survival advantage for patients with stage IB tumors ≥4 cm treated with adjuvant chemotherapy |
In use |
(4,16) |
| Genetic signatures |
| Pervenio Lung RS (Life Technologies); myPlan Lung (Myriad) |
Prognostic |
Risk stratification |
Under investigation |
(22) |
| Tumor-based proteomics |
| ERCC1 |
Predictive |
Correlation between absence of ERCC1 expression and platinum response failed to validate due to assay variabilities |
Failed to validate |
(23,24) |
| Molecular targets from the advanced setting |
| EGFR, ALK |
Predictive/prognostic |
ALCHEMIST study to determine the role of genomic profiling and molecular targets and therapies for early-stage lung cancer |
Under investigation |
(25) |
| PD-L1 |
Predictive/prognostic |
PEARLS study to evaluate pembrolizumab after surgery and standard chemotherapy |
Under investigation |
(26) |
